BRIEF CO‐ADMINISTRATION OF IDELALISIB MAY IMPROVE THE LONG‐TERM EFFICACY OF FRONTLINE CHEMOIMMUNOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKAEMIA: 3‐YEAR FOLLOW‐UP FROM THE RIALTO TRIAL. (12th June 2019) - Pettitt, A.; Kalakonda, N.; Cicconi, S.; Murphy, C.; Menon, G.; Coupland, S.E.; Oates, M.; Lin, K.; Pocock, C.; Jenkins, S.; Schuh, A.; Wandroo, F.; et al.